> Gabapentin ER might be able to find a sweet spot in between Lyrica and the generic. <
Dew, I think that is what they will hit on. If they are only off by a small number of pain-free days relative to Lyrica then they will be able to siphon good market share. It seems many specialty pharmas can make it big with delayed release formulations.
Still waiting for cheaper biologics via transgenic milk to help me retire :-)
Market Data 
Markets 
AI
